Equities research analysts expect The Joint Corp. (NASDAQ:JYNT) to announce sales of $13.57 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for The Joint's earnings, with estimates ranging from $13.16 million to $13.99 million. The Joint posted sales of $12.73 million during the same quarter last year, which indicates a positive year-over-year growth rate of 6.6%. The company is expected to announce its next earnings report on Thursday, November 5th.
According to Zacks, analysts expect that The Joint will report full-year sales of $54.80 million for the current financial year, with estimates ranging from $54.44 million to $55.16 million. For the next financial year, analysts anticipate that the company will report sales of $67.17 million, with estimates ranging from $64.28 million to $70.07 million. Zacks Investment Research's sales averages are an average based on a survey of sell-side research firms that follow The Joint.
The Joint (NASDAQ:JYNT) last issued its earnings results on Thursday, August 6th. The company reported $0.01 EPS for the quarter, beating the Zacks' consensus estimate of ($0.06) by $0.07. The Joint had a return on equity of 47.43% and a net margin of 5.38%. The company had revenue of $12.59 million during the quarter, compared to the consensus estimate of $10.13 million.
JYNT has been the subject of a number of research reports. BidaskClub downgraded The Joint from a "hold" rating to a "sell" rating in a research note on Thursday, September 3rd. Craig Hallum started coverage on The Joint in a research report on Thursday, June 25th. They set a "buy" rating and a $24.00 price objective for the company. Zacks Investment Research upgraded The Joint from a "hold" rating to a "buy" rating and set a $16.00 price objective for the company in a research report on Saturday, August 8th. ValuEngine upgraded The Joint from a "hold" rating to a "buy" rating in a research report on Wednesday, July 8th. Finally, Maxim Group reiterated a "buy" rating and set a $22.00 price objective on shares of The Joint in a research report on Friday, August 7th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The Joint presently has an average rating of "Buy" and an average target price of $20.60.
Large investors have recently made changes to their positions in the stock. Citigroup Inc. raised its holdings in The Joint by 42.7% during the first quarter. Citigroup Inc. now owns 3,738 shares of the company's stock worth $41,000 after purchasing an additional 1,119 shares in the last quarter. BNP Paribas Arbitrage SA raised its holdings in The Joint by 120.9% during the first quarter. BNP Paribas Arbitrage SA now owns 4,019 shares of the company's stock worth $44,000 after purchasing an additional 2,200 shares in the last quarter. Marshall Wace North America L.P. bought a new stake in The Joint during the first quarter worth approximately $47,000. SG Americas Securities LLC bought a new stake in The Joint during the second quarter worth approximately $112,000. Finally, Mackenzie Financial Corp bought a new stake in The Joint during the first quarter worth approximately $116,000. 77.28% of the stock is currently owned by hedge funds and other institutional investors.
Shares of JYNT stock opened at $19.06 on Friday. The company has a quick ratio of 1.27, a current ratio of 1.27 and a debt-to-equity ratio of 0.49. The business has a 50 day moving average of $17.81 and a two-hundred day moving average of $14.93. The Joint has a 52 week low of $7.67 and a 52 week high of $21.75. The company has a market cap of $266.98 million, a P/E ratio of 95.28 and a beta of 1.10.
The Joint Company Profile
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising and the sale of regional developer rights.
See Also: What is the return on assets (ROA) ratio?
Get a free copy of the Zacks research report on The Joint (JYNT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
15 Technology Stocks that Analysts Love
There are more than 1,100 technology companies traded on public markets in the United States. Given the sheer number of hardware makers, social networks, software companies, service providers and other tech stocks, it can be hard to identify which tech companies are going to outperform the market.
Fortunately, Wall Street's brightest minds have already done this for us. Every year, analyst issue approximately 15,000 distinct recommendations for technology companies. Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firm are giving "strong buy" and "buy" ratings to the same tech stock.
This slide show lists the 15 technology companies that have the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.
View the "15 Technology Stocks that Analysts Love".